Global Autologous Wound Patches Market 2023-2030

Description

List of Tables

Global Autologous Wound Patches Market Size, Share & Trends Analysis Report by Type (Platelet Rich Plasma and Platelet Rich Fibrin), by Application (Acute wound and chronic wound), and by End-User (Hospitals, Clinics, and Ambulatory Surgical Center), Forecast Period (2023-2030)

The global autologous wound patches market is anticipated to grow at a CAGR of 9.2% during the forecast period (2023-2030). Autologous wound patches offer new treatment option for patients, as they can help to accelerate wound healing and reduce the risk of complications. Skin injuries across the body continue to disrupt everyday life for millions of patients and result in prolonged hospital stays, infection, and death. Advances in wound healing devices have improved clinical practice but have mainly focused on treating macroscale healing versus underlying microscale pathophysiology. Consensus is lacking on optimal treatment strategies using a spectrum of wound healing products, which has motivated the design of new therapies.

Segmental Outlook

The global autologous wound patches market is segmented on the type, application, and end-user. Based on the type, the market is sub-segmented into platelet rich plasma and platelet rich fibrin. Based on application, the market is sub-segmented into acute wound and chronic wound. Based on the end-user, the market is sub-segmented into a hospitals, clinics, and ambulatory surgical center. Among the type, the Platelet rich fibrin sub-segment is anticipated to hold a considerable share of the market, owing to factor which includes, it spun at a lower speed, which allows some of the white blood cells & stem cells to remain intact with the platelet layer, as a result, more healing factors are present in platelet rich fibrin patches, which supports faster healing of chronic wounds.

The chronic wound Sub-Segment is Anticipated to Hold a Considerable Share of the Global Autologous wound patches Market

Among the application, the chronic wound sub-segment is expected to hold a considerable share of the global Autologous wound patches market. This segmental growth is attributed to several factor such as, chronic wounds, advanced bandages target the dysregulated inflammatory phase, replace skin tissue, and protect against infection. In diabetic wounds, recent attention focused on jump-starting the healing process by inducing acute inflammation. The preventive delivery of a mast cell stabilizer and the release of the neuropeptide substance P both induced strong inflammation after wounding, improved wound re-epithelialization, and accelerated wound healing in diabetic mice. According to World health organization, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.

Regional Outlook

The global autologous wound patches market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to Increasing number of road and traumatic accidents in the region, leading to a rise in the number of patients with complex wounds. Autologous wound patches are particularly suitable for treating these types of wounds, as they can help to promote tissue regeneration and repair the damage easily.

The European Region is Expected to Grow at a Significant CAGR in the Global Autologous wound patches Market

Among all regions, the European regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to medical advancements and innovation in the region. There is a growing focus on developing new and innovative autologous wound patches with improved properties such as faster healing times, reduced pain and discomfort, and ease of use. For instance, In July 2023, RedDress, a personalized and autologous wound care solution created from patients own whole blood, announced that its ActiGraft PRO product is now commercially available throughout the US and is eligible for reimbursement nationally from Medicare and Medicare Advantage via NCD 270.3 and G-0465 & G-0460 codes. it enables health care providers to produce, 'in real time' in vitro blood clots from a patient's own blood. Once applied, the blood clot serves as a protective covering and supports the body's natural wound healing response. it can be used for a wide variety of hard-to-treat chronic wounds, including diabetic foot ulcers, pressure injuries, venous ulcers, traumatic wounds and post-surgical wounds.

Market Players Outlook

The major companies serving the autologous wound patches market include Reapplix, PRP Concepts, RedDress, Nuo Therapeutics, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In August 2023, RedDress, developers of the ActiGraft PRO system, a personalized and autologous wound care solution created from patients' own whole blood, announced that its ActiGraft PRO product is now available through Vizient, the nation's largest provider-driven healthcare performance improvement company. Additionally, it announced also established a strategic partnership with OneMed, part of the Asker Healthcare Group, to commercialize and distribute the ActiGraft system throughout Finland.

The Report Covers:

Market value data analysis of 2022 and forecast to 2030.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global autologous wound patches market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2027930

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. PRP Concepts
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Reapplix A/S
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. RedDress
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Key Strategy Analysis

4. Market Segmentation

4.1. Global Autologous wound patches Market by Type
- 4.1.1. Platelet Rich Plasma
- 4.1.2. Platelet Rich Fibrin
4.2. Global Autologous wound patches Market by Application
- 4.2.1. Acute wound
- 4.2.2. Chronic wound
4.3. Global Autologous wound patches Market by End-User
- 4.3.1. Hospitals
- 4.3.2. Clinics
- 4.3.3. Ambulatory Surgical Center

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. 3M Healthcare
6.2. ACell Inc.
6.3. Advanced BioHealing
6.4. AlloSource
6.5. Avita Medical
6.6. Coloplast
6.7. ConvaTec
6.8. Integra LifeSciences Corp
6.9. MiMedx Group, Inc.
6.10. Molnlycke Health Care AB
6.11. Nuo Therapeutics
6.12. NuVasive
6.13. Organogenesis Holdings Inc.
6.14. Osiris Therapeutics, Inc.
6.15. Smith & Nephew plc
6.16. TissueTech, Inc.